Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers

David J. Hughes, Sophie M. Ginolhac, Isabelle Coupier, Marilys Corbex, Brigitte Bressac-De-Paillerets, Agnès Chompret, Yves Jean Bignon, Nancy Uhrhammer, Christine Lasset, Sophie Giraud, Agnès Hardouin, Pascaline Berthet, Jean Philippe Peyrat, Joelle Fournier, Catherine Nogues, Rosette Lidereau, Danièle Muller, Jean Pierre Fricker, Michel Longy, Christine Toulas & 14 others Rosine Guimbaud, Christine Maugard, Sylviane Olschwang, Drakoulis Yannoukakos, Francine Durocher, Anne Marie Moisan, Jacques Simard, Sylvie Mazoyer, Henry T. Lynch, Csilla Szabo, Gilbert M. Lenoir, David E. Goldgar, Dominique Stoppa-Lyonnet, Olga M. Sinilnikova

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and ovarian cancer. As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5′-untranslated region (203G > A) of the BRCA2 gene modify breast or ovarian cancer risk in BRCA1 mutation carriers. The study includes 778 women carrying a BRCA1 germ-line mutation belonging to 403 families. The two BRCA2 variants were analyzed by the TaqMan allelic discrimination technique. Genotypes were analyzed by disease-free survival analysis using a Cox proportional hazards model. We found no evidence of a significant modification of breast cancer penetrance in BRCA1 mutation carriers by either polymorphism. In respect of ovarian cancer risk, we also saw no effect with the N372H variant but we did observe a borderline association with the 5′-untranslated region 203A allele (hazard ratio, 1.43; CI, 1.01-2.00). In contrast to the result of Healey et al. on newborn females and adult female controls, we found no departure from Hardy-Weinberg equilibrium in the distribution of N372H alleles for our female BRCA1 carriers. We conclude that if these single-nucleotide polymorphisms do modify the risk of cancer in BRCA1 mutation carriers, their effects are not significantly larger than that of N372H previously observed in the general population.

Original languageEnglish
Pages (from-to)265-267
Number of pages3
JournalCancer Epidemiology Biomarkers and Prevention
Volume14
Issue number1
StatePublished - Jan 2005

Fingerprint

Ovarian Neoplasms
BRCA2 Gene
Breast Neoplasms
Mutation
5' Untranslated Regions
Alleles
Genotype
Penetrance
Germ-Line Mutation
Amino Acid Substitution
Survival Analysis
Proportional Hazards Models
Disease-Free Survival
Single Nucleotide Polymorphism
Neoplasms
Newborn Infant
Population

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Hughes, D. J., Ginolhac, S. M., Coupier, I., Corbex, M., Bressac-De-Paillerets, B., Chompret, A., ... Sinilnikova, O. M. (2005). Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiology Biomarkers and Prevention, 14(1), 265-267.

Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. / Hughes, David J.; Ginolhac, Sophie M.; Coupier, Isabelle; Corbex, Marilys; Bressac-De-Paillerets, Brigitte; Chompret, Agnès; Bignon, Yves Jean; Uhrhammer, Nancy; Lasset, Christine; Giraud, Sophie; Hardouin, Agnès; Berthet, Pascaline; Peyrat, Jean Philippe; Fournier, Joelle; Nogues, Catherine; Lidereau, Rosette; Muller, Danièle; Fricker, Jean Pierre; Longy, Michel; Toulas, Christine; Guimbaud, Rosine; Maugard, Christine; Olschwang, Sylviane; Yannoukakos, Drakoulis; Durocher, Francine; Moisan, Anne Marie; Simard, Jacques; Mazoyer, Sylvie; Lynch, Henry T.; Szabo, Csilla; Lenoir, Gilbert M.; Goldgar, David E.; Stoppa-Lyonnet, Dominique; Sinilnikova, Olga M.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 14, No. 1, 01.2005, p. 265-267.

Research output: Contribution to journalArticle

Hughes, DJ, Ginolhac, SM, Coupier, I, Corbex, M, Bressac-De-Paillerets, B, Chompret, A, Bignon, YJ, Uhrhammer, N, Lasset, C, Giraud, S, Hardouin, A, Berthet, P, Peyrat, JP, Fournier, J, Nogues, C, Lidereau, R, Muller, D, Fricker, JP, Longy, M, Toulas, C, Guimbaud, R, Maugard, C, Olschwang, S, Yannoukakos, D, Durocher, F, Moisan, AM, Simard, J, Mazoyer, S, Lynch, HT, Szabo, C, Lenoir, GM, Goldgar, DE, Stoppa-Lyonnet, D & Sinilnikova, OM 2005, 'Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers', Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 1, pp. 265-267.
Hughes DJ, Ginolhac SM, Coupier I, Corbex M, Bressac-De-Paillerets B, Chompret A et al. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiology Biomarkers and Prevention. 2005 Jan;14(1):265-267.
Hughes, David J. ; Ginolhac, Sophie M. ; Coupier, Isabelle ; Corbex, Marilys ; Bressac-De-Paillerets, Brigitte ; Chompret, Agnès ; Bignon, Yves Jean ; Uhrhammer, Nancy ; Lasset, Christine ; Giraud, Sophie ; Hardouin, Agnès ; Berthet, Pascaline ; Peyrat, Jean Philippe ; Fournier, Joelle ; Nogues, Catherine ; Lidereau, Rosette ; Muller, Danièle ; Fricker, Jean Pierre ; Longy, Michel ; Toulas, Christine ; Guimbaud, Rosine ; Maugard, Christine ; Olschwang, Sylviane ; Yannoukakos, Drakoulis ; Durocher, Francine ; Moisan, Anne Marie ; Simard, Jacques ; Mazoyer, Sylvie ; Lynch, Henry T. ; Szabo, Csilla ; Lenoir, Gilbert M. ; Goldgar, David E. ; Stoppa-Lyonnet, Dominique ; Sinilnikova, Olga M. / Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. In: Cancer Epidemiology Biomarkers and Prevention. 2005 ; Vol. 14, No. 1. pp. 265-267.
@article{81d9cc4f94244ccd864a6412b41212da,
title = "Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers",
abstract = "The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and ovarian cancer. As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5′-untranslated region (203G > A) of the BRCA2 gene modify breast or ovarian cancer risk in BRCA1 mutation carriers. The study includes 778 women carrying a BRCA1 germ-line mutation belonging to 403 families. The two BRCA2 variants were analyzed by the TaqMan allelic discrimination technique. Genotypes were analyzed by disease-free survival analysis using a Cox proportional hazards model. We found no evidence of a significant modification of breast cancer penetrance in BRCA1 mutation carriers by either polymorphism. In respect of ovarian cancer risk, we also saw no effect with the N372H variant but we did observe a borderline association with the 5′-untranslated region 203A allele (hazard ratio, 1.43; CI, 1.01-2.00). In contrast to the result of Healey et al. on newborn females and adult female controls, we found no departure from Hardy-Weinberg equilibrium in the distribution of N372H alleles for our female BRCA1 carriers. We conclude that if these single-nucleotide polymorphisms do modify the risk of cancer in BRCA1 mutation carriers, their effects are not significantly larger than that of N372H previously observed in the general population.",
author = "Hughes, {David J.} and Ginolhac, {Sophie M.} and Isabelle Coupier and Marilys Corbex and Brigitte Bressac-De-Paillerets and Agn{\`e}s Chompret and Bignon, {Yves Jean} and Nancy Uhrhammer and Christine Lasset and Sophie Giraud and Agn{\`e}s Hardouin and Pascaline Berthet and Peyrat, {Jean Philippe} and Joelle Fournier and Catherine Nogues and Rosette Lidereau and Dani{\`e}le Muller and Fricker, {Jean Pierre} and Michel Longy and Christine Toulas and Rosine Guimbaud and Christine Maugard and Sylviane Olschwang and Drakoulis Yannoukakos and Francine Durocher and Moisan, {Anne Marie} and Jacques Simard and Sylvie Mazoyer and Lynch, {Henry T.} and Csilla Szabo and Lenoir, {Gilbert M.} and Goldgar, {David E.} and Dominique Stoppa-Lyonnet and Sinilnikova, {Olga M.}",
year = "2005",
month = "1",
language = "English",
volume = "14",
pages = "265--267",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers

AU - Hughes, David J.

AU - Ginolhac, Sophie M.

AU - Coupier, Isabelle

AU - Corbex, Marilys

AU - Bressac-De-Paillerets, Brigitte

AU - Chompret, Agnès

AU - Bignon, Yves Jean

AU - Uhrhammer, Nancy

AU - Lasset, Christine

AU - Giraud, Sophie

AU - Hardouin, Agnès

AU - Berthet, Pascaline

AU - Peyrat, Jean Philippe

AU - Fournier, Joelle

AU - Nogues, Catherine

AU - Lidereau, Rosette

AU - Muller, Danièle

AU - Fricker, Jean Pierre

AU - Longy, Michel

AU - Toulas, Christine

AU - Guimbaud, Rosine

AU - Maugard, Christine

AU - Olschwang, Sylviane

AU - Yannoukakos, Drakoulis

AU - Durocher, Francine

AU - Moisan, Anne Marie

AU - Simard, Jacques

AU - Mazoyer, Sylvie

AU - Lynch, Henry T.

AU - Szabo, Csilla

AU - Lenoir, Gilbert M.

AU - Goldgar, David E.

AU - Stoppa-Lyonnet, Dominique

AU - Sinilnikova, Olga M.

PY - 2005/1

Y1 - 2005/1

N2 - The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and ovarian cancer. As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5′-untranslated region (203G > A) of the BRCA2 gene modify breast or ovarian cancer risk in BRCA1 mutation carriers. The study includes 778 women carrying a BRCA1 germ-line mutation belonging to 403 families. The two BRCA2 variants were analyzed by the TaqMan allelic discrimination technique. Genotypes were analyzed by disease-free survival analysis using a Cox proportional hazards model. We found no evidence of a significant modification of breast cancer penetrance in BRCA1 mutation carriers by either polymorphism. In respect of ovarian cancer risk, we also saw no effect with the N372H variant but we did observe a borderline association with the 5′-untranslated region 203A allele (hazard ratio, 1.43; CI, 1.01-2.00). In contrast to the result of Healey et al. on newborn females and adult female controls, we found no departure from Hardy-Weinberg equilibrium in the distribution of N372H alleles for our female BRCA1 carriers. We conclude that if these single-nucleotide polymorphisms do modify the risk of cancer in BRCA1 mutation carriers, their effects are not significantly larger than that of N372H previously observed in the general population.

AB - The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and ovarian cancer. As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5′-untranslated region (203G > A) of the BRCA2 gene modify breast or ovarian cancer risk in BRCA1 mutation carriers. The study includes 778 women carrying a BRCA1 germ-line mutation belonging to 403 families. The two BRCA2 variants were analyzed by the TaqMan allelic discrimination technique. Genotypes were analyzed by disease-free survival analysis using a Cox proportional hazards model. We found no evidence of a significant modification of breast cancer penetrance in BRCA1 mutation carriers by either polymorphism. In respect of ovarian cancer risk, we also saw no effect with the N372H variant but we did observe a borderline association with the 5′-untranslated region 203A allele (hazard ratio, 1.43; CI, 1.01-2.00). In contrast to the result of Healey et al. on newborn females and adult female controls, we found no departure from Hardy-Weinberg equilibrium in the distribution of N372H alleles for our female BRCA1 carriers. We conclude that if these single-nucleotide polymorphisms do modify the risk of cancer in BRCA1 mutation carriers, their effects are not significantly larger than that of N372H previously observed in the general population.

UR - http://www.scopus.com/inward/record.url?scp=19944430865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944430865&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 265

EP - 267

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 1

ER -